ref_name,subject_name,collection_date,section,note,date_added
Lee22,Patient A,2020-05-15,Supplementary data: accession numbers,Obinutuzumab/anti-CD20,2022-02-07
Lee22,Patient B,2020-09-23,Supplementary data: accession numbers,Obinutuzumab-venetoclax/anti-CD20,2022-02-07
Lee22,Patient B,2020-11-09,Supplementary data: accession numbers,Obinutuzumab-venetoclax/anti-CD20,2022-02-07
Lee22,Patient C,2020-03-19,Supplementary data: accession numbers,R-EPOCH/anti-CD20,2022-02-07
Lee22,Patient C,2020-04-03,Supplementary data: accession numbers,R-EPOCH/anti-CD20,2022-02-07
Lee22,Patient C,2020-04-14,Supplementary data: accession numbers,R-EPOCH/anti-CD20,2022-02-07
Lee22,Patient C,2020-04-22,Supplementary data: accession numbers,R-EPOCH/anti-CD20,2022-02-07
Lee22,Patient C,2020-05-28,Supplementary data: accession numbers,R-EPOCH/anti-CD20,2022-02-07
Lee22,Patient D,2020-04-01,Supplementary data: accession numbers,Obinutuzumab-bendamustine/anti-CD20,2022-02-07
Lee22,Patient D,2020-05-08,Supplementary data: accession numbers,Obinutuzumab-bendamustine/anti-CD20,2022-02-07
Lee22,Patient D,2020-08-27,Supplementary data: accession numbers,Obinutuzumab-bendamustine/anti-CD20,2022-02-07
Lee22,Patient D,2020-09-23,Supplementary data: accession numbers,Obinutuzumab-bendamustine/anti-CD20,2022-02-07
Lee22,Patient D,2021-01-20,Supplementary data: accession numbers,Obinutuzumab-bendamustine/anti-CD20,2022-02-07
Lee22,Patient D,2021-02-22,Supplementary data: accession numbers,Obinutuzumab-bendamustine/anti-CD20,2022-02-07
Lee22,Patient D,2021-02-26,Supplementary data: accession numbers,Obinutuzumab-bendamustine/anti-CD20,2022-02-07
Lee22,Patient D,2021-03-09,Supplementary data: accession numbers,Obinutuzumab-bendamustine/anti-CD20,2022-02-07
Lee22,Patient E,2020-03-18,Supplementary data: accession numbers,R-DHAX/anti-CD20,2022-02-07
Lee22,Patient E,2020-05-06,Supplementary data: accession numbers,R-DHAX/anti-CD20,2022-02-07
Lee22,Patient E,2020-05-27,Supplementary data: accession numbers,R-DHAX/anti-CD20,2022-02-07
Lee22,Patient F,2020-05-11,Supplementary data: accession numbers,AlloSCT,2022-02-07
Lee22,Patient F,2020-05-25,Supplementary data: accession numbers,AlloSCT,2022-02-07
Lee22,Patient F,2020-06-03,Supplementary data: accession numbers,AlloSCT,2022-02-07
Lee22,Patient F,2020-06-13,Supplementary data: accession numbers,AlloSCT,2022-02-07
Lee22,Patient F,2020-06-16,Supplementary data: accession numbers,AlloSCT,2022-02-07
Lee22,Patient G,2020-04-13,Supplementary data: accession numbers,Venetoclax,2022-02-07
Lee22,Patient G,2020-05-07,Supplementary data: accession numbers,Venetoclax,2022-02-07
Lee22,Patient G,2020-05-29,Supplementary data: accession numbers,Venetoclax,2022-02-07
Lee22,Patient H,2020-12-31,Supplementary data: accession numbers,AlloSCT,2022-02-07
Lee22,Patient H,2021-01-18,Supplementary data: accession numbers,AlloSCT,2022-02-07
Lee22,Patient H,2021-01-30,Supplementary data: accession numbers,AlloSCT,2022-02-07
Lee22,Patient I,2021-01-07,Supplementary data: accession numbers,CAR T cell,2022-02-07
Lee22,Patient I,2021-03-01,Supplementary data: accession numbers,CAR T cell,2022-02-07
Lee22,Patient J,2020-12-03,Supplementary data: accession numbers,Rituximab/anti-CD20,2022-02-07
Lee22,Patient J,2020-12-12,Supplementary data: accession numbers,Rituximab/anti-CD20,2022-02-07
Lee22,Patient J,2020-12-16,Supplementary data: accession numbers,Rituximab/anti-CD20,2022-02-07
Lee22,Patient J,2020-12-19,Supplementary data: accession numbers,Rituximab/anti-CD20,2022-02-07
Lee22,Patient K,2020-04-22,Supplementary data: accession numbers,Obinutuzumab/anti-CD20,2022-02-07
Lee22,Patient K,2020-05-01,Supplementary data: accession numbers,Obinutuzumab/anti-CD20,2022-02-07
Lee22,Patient K,2020-05-07,Supplementary data: accession numbers,Obinutuzumab/anti-CD20,2022-02-07
Lee22,Patient K,2020-05-13,Supplementary data: accession numbers,Obinutuzumab/anti-CD20,2022-02-07
Lee22,Patient K,2020-05-26,Supplementary data: accession numbers,Obinutuzumab/anti-CD20,2022-02-07
Lee22,Patient K,2020-05-27,Supplementary data: accession numbers,Obinutuzumab/anti-CD20,2022-02-07
Lee22,Patient K,2020-06-12,Supplementary data: accession numbers,Obinutuzumab/anti-CD20,2022-02-07
Lee22,Patient K,2020-06-14,Supplementary data: accession numbers,Obinutuzumab/anti-CD20,2022-02-07
Lee22,Patient K,2020-06-16,Supplementary data: accession numbers,Obinutuzumab/anti-CD20,2022-02-07
Lee22,Patient K,2020-06-18,Supplementary data: accession numbers,Obinutuzumab/anti-CD20,2022-02-07
Lee22,Patient K,2020-06-25,Supplementary data: accession numbers,Obinutuzumab/anti-CD20,2022-02-07
Lee22,Patient L,2020-04-02,Supplementary data: accession numbers,Obinutuzumab-CHOP/anti-CD20,2022-02-07
Lee22,Patient L,2020-06-05,Supplementary data: accession numbers,Obinutuzumab-CHOP/anti-CD20,2022-02-07
Lee22,Patient M,2021-02-05,Supplementary data: accession numbers,CAR T cell/anti-CD20,2022-02-07
Lee22,Patient M,2021-03-03,Supplementary data: accession numbers,CAR T cell/anti-CD20,2022-02-07
Lee22,Patient O,2020-12-18,Supplementary data: accession numbers,R-CHOP/anti-CD20,2022-02-07
Lee22,Patient O,2020-12-23,Supplementary data: accession numbers,R-CHOP/anti-CD20,2022-02-07
Lee22,Patient O,2020-12-30,Supplementary data: accession numbers,R-CHOP/anti-CD20,2022-02-07
Lee22,Patient O,2021-01-13,Supplementary data: accession numbers,R-CHOP/anti-CD20,2022-02-07
Lee22,Patient P,2020-07-30,Supplementary data: accession numbers,R-bendamustine-polatuzumab/anti-CD20,2022-02-07
Lee22,Patient P,2020-11-19,Supplementary data: accession numbers,R-bendamustine-polatuzumab/anti-CD20,2022-02-07
Lee22,Patient Q,2020-03-25,Supplementary data: accession numbers,AlloSCT/anti-CD20,2022-02-07
Lee22,Patient Q,2020-04-24,Supplementary data: accession numbers,AlloSCT/anti-CD20,2022-02-07
Lee22,Patient R,2020-04-27,Supplementary data: accession numbers,Obinutuzumab/anti-CD20,2022-02-07
Lee22,Patient R,2020-05-02,Supplementary data: accession numbers,Obinutuzumab/anti-CD20,2022-02-07
Lee22,Patient R,2020-05-16,Supplementary data: accession numbers,Obinutuzumab/anti-CD20,2022-02-07
Lee22,Patient R,2020-05-19,Supplementary data: accession numbers,Obinutuzumab/anti-CD20,2022-02-07
